Lawrence Otto Klein's most recent trade in Jade Biosciences Inc was a trade of 23,017 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jade Biosciences Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 23,017 | 23,017 | - | - | Stock Option (Right to Buy) | |
| Oruka Therapeutics Inc | Lawrence Otto Klein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 230,000 | 230,000 | - | - | Employee Stock Option (right to buy) | |
| Jasper Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 47,000 | 47,000 | - | - | Stock Option (right to buy) | |
| Jasper Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 24,500 | 24,500 | - | 0 | Voting Common Stock | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 12,500 | 12,500 | - | - | Restricted Stock Units | |
| Dyne Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 7,222 | 7,222 | - | - | Stock Option (right to buy) | |
| Dyne Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| Jasper Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 78,045 | 78,045 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 4,584 | 26,909 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 4,584 | 4,583 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,000 | 9,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,000 | 28,026 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.56 per share. | 10 Mar 2022 | 1,883 | 25,026 (0%) | 0% | 62.6 | 117,800 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.08 per share. | 10 Mar 2022 | 1,229 | 26,797 (0%) | 0% | 61.1 | 75,067 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 46,200 | 46,200 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 20,400 | 20,400 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 26,667 | 33,510 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 26,667 | 13,333 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.17 per share. | 03 Dec 2021 | 11,185 | 22,325 (0%) | 0% | 69.2 | 773,666 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 13,800 | 13,800 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 11,050 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.86 per share. | 10 Sep 2021 | 4,207 | 6,843 (0%) | 0% | 117.9 | 495,837 | Common Shares |
| Dyne Therapeutics Inc | Lawrence Otto Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Sale of securities on an exchange or to another person at price $ 128.20 per share. | 23 Mar 2021 | 88,000 | 13,050 (0%) | 0% | 128.2 | 11,281,600 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.49 per share. | 23 Mar 2021 | 22,000 | 47,050 (0%) | 0% | 51.5 | 1,132,780 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 22,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 20,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.87 per share. | 23 Mar 2021 | 20,000 | 77,050 (0%) | 0% | 40.9 | 817,400 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.67 per share. | 23 Mar 2021 | 12,000 | 25,050 (0%) | 0% | 44.7 | 536,040 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 23 Mar 2021 | 12,000 | 89,050 (0%) | 0% | 14.4 | 173,160 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.66 per share. | 23 Mar 2021 | 12,000 | 101,050 (0%) | 0% | 17.7 | 211,920 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Sale of securities on an exchange or to another person at price $ 126.97 per share. | 23 Mar 2021 | 12,000 | 1,050 (0%) | 0% | 127.0 | 1,523,640 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 12,000 | 2,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 12,000 | 3,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 12,000 | 43,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.87 per share. | 23 Mar 2021 | 10,000 | 57,050 (0%) | 0% | 29.9 | 298,700 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 33,334 | 33,334 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 12,000 | 12,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 4,583 | 15,191 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.15 per share. | 10 Mar 2021 | 2,141 | 13,050 (0%) | 0% | 124.1 | 265,805 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.43 per share. | 15 Jan 2021 | 16,334 | 26,942 (0%) | 0% | 14.4 | 235,700 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.11 per share. | 02 Jan 2021 | 9,392 | 10,608 (0%) | 0% | 153.1 | 1,438,009 | Common Shares |
| CRISPR Therapeutics AG | Lawrence Otto Klein | CBO & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2020 | 16,666 | 16,666 | - | - | Stock Option (Right to Buy) |